Clinical background
===================

C-type natriuretic peptide (CNP) is a 22-amino-acid peptide produced mainly in the endothelium with potent cardiac unloading and blood pressure lowering actions, but minimal renal actions. Based on our previous knowledge, we recently fused a 6 aa sequence from BNP to the C-terminus and a 5 aa sequence from ANP to the N-terminus of CNP. This novel hybrid peptide, CBA-NP, has cardiac unloading actions and mild hypotensive effects similar to CNP. Importantly however, the N and C terminus alterations resulted in potent renal excretory actions. Here we test the hypothesis that the 3 aa GSM~15--17~in the disulfide-ring mediate the vascular and hypotensive actions of CBA-NP. We therefore mutated GSM ~15--17~to REA~15--17~, which we named ABC-NP and compared its *in vivo*and *in vitro*actions to CBA-NP.

Methods
=======

We determined the cardiorenal and humoral actions of intravenous bolus administration of CBA-NP (n = 5) and ABC-NP (n = 5) at 25 mg/kg in two separate groups of normal anesthetized dogs. We also assessed the cGMP response of both peptides in human aortic endothelial cells (HAEC), human cardiac fibroblast (HCF) and isolated canine glomeruli. \* p \< 0.05.

Results
=======

IV bolus administration of CBA-NP and ABC-NP resulted in diuresis\* and natriuresis\*. There was a significant decrease in mean arterial blood (MAP) pressure with CBA-NP\* but no change with ABC-NP. In addition, the reduction in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) was significantly greater with CBA-NP as compared to ABC-NP. cGMP generation in HAEC and HCF was minimal with ABC-NP and was significantly higher with CBA-NP\*. In contrast, cGMP generation was similar in isolated glomeruli between the two peptides.

Conclusion
==========

Our studies demonstrates that mutation of three amino acid (aa) residues within the CNP ring of CBA-NP from GSM ~15--17~to REA alters the vascular but not the renal excretory properties. Hence by this minimal mutation within the ring of CBA-NP, we have designed a renal specific peptide ABC-NP resulting in new sequence specific functional information which can be used to design organ specific therapeutic peptides with unique properties tailored for a specific disease state.
